艾地苯醌
医学
自然史
Leber遗传性视神经病
疾病
重症监护医学
语句(逻辑)
家庭医学
视神经病变
病理
政治学
药理学
眼科
内科学
法学
视神经
作者
Valério Carelli,Michele Carbonelli,I.F.M. de Coo,Aki Kawasaki,Thomas Klopstock,Wolf Alexander Lagrèze,Chiara La Morgia,Nancy J. Newman,Christophe Orssaud,Jan Willem R. Pott,Alfredo Arrigo Sadun,Judith Van Everdingen,Catherine Vignal‐Clermont,Marcela Votruba,Patrick Yu‐Wai‐Man,Piero Barboni
标识
DOI:10.1097/wno.0000000000000570
摘要
Leber hereditary optic neuropathy (LHON) is currently estimated as the most frequent mitochondrial disease (1 in 27,000-45,000). Its molecular pathogenesis and natural history is now fairly well understood. LHON also is the first mitochondrial disease for which a treatment has been approved (idebenone-Raxone, Santhera Pharmaceuticals) by the European Medicine Agency, under exceptional circumstances because of the rarity and severity of the disease. However, what remains unclear includes the optimal target population, timing, dose, and frequency of administration of idebenone in LHON due to lack of accepted definitions, criteria, and general guidelines for the clinical management of LHON. To address these issues, a consensus conference with a panel of experts from Europe and North America was held in Milan, Italy, in 2016. The intent was to provide expert consensus statements for the clinical and therapeutic management of LHON based on the currently available evidence. We report the conclusions of this conference, providing the guidelines for clinical and therapeutic management of LHON.
科研通智能强力驱动
Strongly Powered by AbleSci AI